The present invention relates to a new and improved formulation of an active enamel substance, such as an enamel matrix, enamel matrix derivative and/or an enamel matrix protein, intended to be used as therapeutic, as prophylactic and/or as cosmetic agent. In the present invention, said active enamel substance is incorporated into a cell-occlusive pharmaceutical and/or therapeutic formulation for administering enamel matrix proteins, comprising a polymeric matrix and at least 80% enamel matrix proteins with a main protein peak at 20kDa, wherein said polymeric matrix comprises a first and a second precursor selected from polyethyleneglycol and wherein the pores of the matrix are smaller than, or no larger than approximately 1 µm. Comprised in the invention is thus in particular a new and cell-occlusive pharmaceutical and/or cosmetic formulation of an active enamel substance, wherein a spatial and/or selective regulation of release of said active enamel substance permits a greater percentage of the active enamel substance to be released at the time of appropriate cellular activity.
